KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of EBT Margin data on record, last reported at 6.78% in Q4 2025.

  • For Q4 2025, EBT Margin rose 888.0% year-over-year to 6.78%; the TTM value through Dec 2025 reached 4.61%, up 658.0%, while the annual FY2025 figure was 4.61%, 658.0% up from the prior year.
  • EBT Margin reached 6.78% in Q4 2025 per AMRX's latest filing, up from 0.67% in the prior quarter.
  • Across five years, EBT Margin topped out at 7.14% in Q2 2025 and bottomed at 41.61% in Q2 2022.
  • Average EBT Margin over 5 years is 1.74%, with a median of 0.01% recorded in 2022.
  • Peak YoY movement for EBT Margin: plummeted -4812bps in 2022, then soared 4656bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 3.04% in 2021, then skyrocketed by 59bps to 1.26% in 2022, then crashed by -978bps to 13.53% in 2023, then skyrocketed by 84bps to 2.1% in 2024, then surged by 423bps to 6.78% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 6.78% in Q4 2025, 0.67% in Q3 2025, and 7.14% in Q2 2025.